Clinical Trials Logo

Autoimmune Disorders clinical trials

View clinical trials related to Autoimmune Disorders.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06434363 Not yet recruiting - Systemic Sclerosis Clinical Trials

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Start date: November 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.